课题基金 / 基金详情

Bevacizumab Delivery to Glioblastoma with MR-Guided Focused Ultrasound

Bevacizumab Delivery to Glioblastoma with MR-Guided Focused Ultrasound
通过 MR 引导聚焦超声将贝伐珠单抗递送至胶质母细胞瘤
批准号:
8628120
负责人:
Richard J. Price
金额:
$7.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-03-01 至 2016-02-29

项目摘要

项目成果

Richard J. Price的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Glioblastoma multiforme (GBM), the most common primary brain cancer, has a 5-year survival rate of only 12%. Poor outcomes are commonplace for GBM patients because chemotherapeutic drugs reach the brain in very low concentrations due to the blood brain barrier (BBB). Biodegradable polymer implants and convection-enhanced delivery approaches circumvent the BBB, but they have only led to moderate improvements in survival. Fortunately, recent clinical trials for GBM with the anti-angiogenesis drug bevacizumab (humanized anti-VEGF IgG) have shown promise, leading to its approval by the FDA for GBM treatment. However, it is also well known that IgG molecules (~150 kD M.W.) do not easily pass through the BBB, suggesting that current bevacizumab treatment is far from optimal. In this proposal, we aim to improve GBM treatment with bevacizumab through the development of an innovative image guided approach that will permit BBB opening to IgG molecules in well-defined locations. Pulsed 1 MHz focused ultrasound (FUS) will be applied to MR-targeted GBMs following the intravenous administration of ultrasound contrast agent microbubbles (MBs). Our pilot studies indicate that the activation of MBs with 1 MHz FUS leads to sonoporation of the BBB without mechanical or thermal damage. We will use 2 specific aims to develop this approach. All studies will use rnu/rnu nude rats with intracranial human Hs683 tumor xenografts. In Aim 1, for given MB diameters, we will define lower FUS pressure thresholds at which the BBB opens to gadolinium and upper FUS pressure thresholds at which thermal tissue injury and/or microvessel damage may begin to occur. These FUS pressure thresholds will then be used as guides for determining optimal FUS and MB diameter parameters for delivering fluorescent tracer IgG molecules across the BBB to Hs683 tumors. In Aim 2, these optimal FUS and MB parameters will be used to determine whether the targeted delivery of bevacizumab to intracranial brain tumors with MR-guided FUS and MBs significantly inhibits tumor growth when compared to standard intravenous administration of the drug. If these pre-clinical studies are successful, we are well positioned for translation to clinical trials. The PI is the Research Director of the UVa FUS Center, which houses InSightec Exablate MR-Guided head and body FUS systems. Our next step for this project would be to verify the safety of the FUS and MB procedures for BBB opening in a large animal model. This would be followed by the initiation of a clinical trial. Clinical trials involving FUS application to the brain have been approved for othr indications at UVa, so there is a clear precedent for translation of his work at our institution.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genome Editing the Blood-Brain Barrier with Sonoselective Focused Ultrasound
  • 批准号:
    10403487
  • 项目类别:
  • 资助金额:
    $59.34万
  • 财政年份:
    2021
  • 负责人:
    Richard J. Price
  • 依托单位:
Genome Editing the Blood-Brain Barrier with Sonoselective Focused Ultrasound
  • 批准号:
    10554403
  • 项目类别:
  • 资助金额:
    $59.35万
  • 财政年份:
    2021
  • 负责人:
    Richard J. Price
  • 依托单位:
ImmunoPET Assessment of anti-CD47 Immunotherapy Delivery to Glioblastoma with Focused Ultrasound
  • 批准号:
    10041000
  • 项目类别:
  • 资助金额:
    $42.01万
  • 财政年份:
    2020
  • 负责人:
    Richard J. Price
  • 依托单位:
Innovative systemic gene therapy for treating Parkinson's disease
  • 批准号:
    10164880
  • 项目类别:
  • 资助金额:
    $50.95万
  • 财政年份:
    2019
  • 负责人:
    Richard J. Price
  • 依托单位:
海外基金